Skip to main content
. Author manuscript; available in PMC: 2014 Nov 15.
Published in final edited form as: Behav Brain Res. 2013 Sep 25;257:10.1016/j.bbr.2013.09.032. doi: 10.1016/j.bbr.2013.09.032

Table 1.

Patient Characteristics

Patient Age Sex Years Diagnosed Education UPDRS
MOCA
MMSE
MA Hemisphere Medication Class LED (mg) Cluster Group
OFF ON OFF ON OFF ON
1 69 M 11 16 29 18 29 30 26 26 L Combination 1038 1
2 61 M 14 18 18 15 29 27 30 29 L Combination 1747.5 1
3 67 M 10 12 29 23 28 29 29 29 R Combination 945.5 1
4 62 F 6 16 9 7 29 28 30 28 R Combination 600 1
5 66 M 7 20 24 24 25 24 30 27 R Combination 840 1
6 57 M 9 16 19 7 30 29 30 30 Both Combination 1100 1
7 64 M 8 16 25 33 30 30 30 30 R L-DOPA 350 1
8 81 M 1 14 23 18 25 25 28 29 L L-DOPA 300 1
9 61 M 4 13 23 16 26 26 30 30 R L-DOPA 900 1
10 72 F 3 18 14 18 27 26 29 30 R L-DOPA 600 1
11 70 M 7 18 --- --- 30 27 28 28 R L-DOPA 698.5 1
12 77 M --- 16 33 33 22 25 29 28 R L-DOPA 400 1
13a 69 M 3 12 28 26 25 25 30 28 L L-DOPA 700 2
14 73 M 2 14 12 17 21 20 27 27 L L-DOPA 300 2
15 61 M 5 16 22 16 19 20 28 28 L Combination 390 2
16b 74 M 5 14 17 20 27 26 29 28 L L-DOPA 600 2
17 67 M 5 16 23 20 26 26 28 30 R L-DOPA 1200 2
18 55 M 6 16 25 21 28 26 29 30 L Combination 925 2
19 69 M 3 18 34 33 27 29 29 27 L L-DOPA 300 2
20 65 F 3 15 11 13 29 26 30 29 R Combination 600 2
21c 84 F 5 14 29 25 21 27 30 30 R L-DOPA 300 2
22 61 M 3 18 14 15 26 26 29 29 L L-DOPA 700 2
23d 68 M 1 16 15 14 22 30 29 29 L L-DOPA 800 2
24 61 M 1 16 12 10 28 25 29 30 L L-DOPA 250 3
25 63 M 3 20 29 28 24 28 28 29 L DA Agonist 160 3
26e 79 M 4 8 30 27 21 25 27 27 L L-DOPA 300 3
27 72 F 8 13 18 18 25 22 28 30 L L-DOPA 600 3
28 55 M 3 12 18 18 27 29 30 30 R L-DOPA 898 3
Mean 67.3 5.2 15.4 21.6 19.7 25.9 26.3 28.9 28.8 662.23
SD 7.5 3.2 2.6 7.2 7.2 3.1 2.7 1.1 1.2 357.67

Abbreviations: --- = No Data; UPDRS-Motor = Unified Parkinson’s Disease Rating Scale-Motor Examination; MMSE = Mini-Mental State Exam; MOCA = Montreal Cognitive Assessment; MA Hemisphere = most affected hemisphere; L-DOPA = Patients treated only with L-DOPA; DA Agonist = Patients treated with only DA agonists; Combination = Patients treated with a combination of L-DOPA and DA agonists; LED = L-DOPA equivalency dose [70]; SD = standard deviation.

a

Data missing for all 500 ms conditions

b

Data missing for the 1500 ms OFF medication condition with the more affected hand

c

Data missing for the 1000 and 1500 ms ON medication conditions with the less affected hand

d

Data missing for the 1000 ms ON medication with the more affected hand

e

Data missing for the 1000 ms OFF medication condition with the more affected hand